Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP696891.RAfERvgj4HGYKCnldId3LPkJRcpSlHZR8I53ZAOyEUpdY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP696891.RAfERvgj4HGYKCnldId3LPkJRcpSlHZR8I53ZAOyEUpdY130_assertion type Assertion NP696891.RAfERvgj4HGYKCnldId3LPkJRcpSlHZR8I53ZAOyEUpdY130_head.
- NP696891.RAfERvgj4HGYKCnldId3LPkJRcpSlHZR8I53ZAOyEUpdY130_assertion wasGeneratedBy ECO_0000203 NP696891.RAfERvgj4HGYKCnldId3LPkJRcpSlHZR8I53ZAOyEUpdY130_provenance.
- NP696891.RAfERvgj4HGYKCnldId3LPkJRcpSlHZR8I53ZAOyEUpdY130_assertion wasDerivedFrom befree-20140225 NP696891.RAfERvgj4HGYKCnldId3LPkJRcpSlHZR8I53ZAOyEUpdY130_provenance.
- NP696891.RAfERvgj4HGYKCnldId3LPkJRcpSlHZR8I53ZAOyEUpdY130_assertion SIO_000772 20426708 NP696891.RAfERvgj4HGYKCnldId3LPkJRcpSlHZR8I53ZAOyEUpdY130_provenance.
- NP696891.RAfERvgj4HGYKCnldId3LPkJRcpSlHZR8I53ZAOyEUpdY130_assertion evidence source_evidence_literature NP696891.RAfERvgj4HGYKCnldId3LPkJRcpSlHZR8I53ZAOyEUpdY130_provenance.
- NP696891.RAfERvgj4HGYKCnldId3LPkJRcpSlHZR8I53ZAOyEUpdY130_assertion description "[Topical monoxidil and oral finasteride are commonly in use and have FDA approval for the treatment of male androgenetic alopecia; dutasteride, a type I and II 5-alpha-reductase inhibitor, is on hold in Phase III trials.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP696891.RAfERvgj4HGYKCnldId3LPkJRcpSlHZR8I53ZAOyEUpdY130_provenance.